Chaitra Gopalappa

List of Publications by Year
in descending order

23	827	687363 13	677142 22
papers	citations	h-index	g-index

24	24	24	1683
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. Mathematical Biosciences and Engineering, 2021, 18, 2150-2181.	1.9	7
2	A reinforcement learning model to inform optimal decision paths for HIV elimination. Mathematical Biosciences and Engineering, 2021, 18, 7666-7684.	1.9	2
3	Agent-based evolving network modeling: a new simulation method for modeling low prevalence infectious diseases. Health Care Management Science, 2021, 24, 623-639.	2.6	6
4	Threshold analyses on combinations of testing, population size, and vaccine coverage for COVID-19 control in a university setting. PLoS ONE, 2021, 16, e0255864.	2.5	14
5	Analysis of Mammography Screening Schedules under Varying Resource Constraints for Planning Breast Cancer Control Programs in Low- and Middle-Income Countries: A Mathematical Study. Medical Decision Making, 2020, 40, 364-378.	2.4	2
6	A Two-Step Markov Processes Approach for Parameterization of Cancer State-Transition Models for Low- and Middle-Income Countries. Medical Decision Making, 2018, 38, 520-530.	2.4	13
7	Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE. Cost Effectiveness and Resource Allocation, 2018, 16, 38.	1.5	27
8	Combinations of interventions to achieve a national HIV incidence reduction goal. Aids, 2017, 31, 2533-2539.	2.2	11
9	Progression and Transmission of HIV/AIDS (PATH 2.0). Medical Decision Making, 2017, 37, 224-233.	2.4	53
10	Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. The Lancet Global Health, 2015, 3, e598-e608.	6.3	46
11	How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV. PLoS ONE, 2014, 9, e111956.	2.5	67
12	The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. Aids, 2014, 28, S5-S14.	2.2	43
13	Updates to the Spectrum model to estimate key HIV indicators for adults and children. Aids, 2014, 28, S427-S434.	2.2	67
14	Exploring the Impact of and Requirements for Adding a Vaccine to the Updated UNAIDS Investment Framework to End AIDS. AIDS Research and Human Retroviruses, 2014, 30, A273-A273.	1.1	0
15	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
16	The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. Aids, 2014, 28, S25-S34.	2.2	33
17	The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy. Aids, 2014, 28, S225-S230.	2.2	15
18	Lifetime Costs and Quality-Adjusted Life Years Saved From HIV Prevention in the Test and Treat Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, e15-e18.	2.1	43

#	Article	IF	Citations
19	Cost-Effectiveness of Screening Men in Maricopa County Jails for Chlamydia and Gonorrhea to Avert Infections in Women. Sexually Transmitted Diseases, 2013, 40, 776-783.	1.7	20
20	Updates of Lifetime Costs of Care and Quality-of-Life Estimates for HIV-Infected Persons in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 183-189.	2.1	113
21	Cost Effectiveness of the National HIV/AIDS Strategy Goal of Increasing Linkage to Care for HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 99-105.	2.1	36
22	Probability model for estimating colorectal polyp progression rates. Health Care Management Science, 2011, 14, 1-21.	2.6	14
23	Removal of Hybridization and Scanning Noise From Microarrays. IEEE Transactions on Nanobioscience, 2009, 8, 210-218.	3.3	7